Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy
Clinical trial NCT05977673 · RECRUITING
Trial details
- NCT number
- NCT05977673
- Sponsor
- Fondazione Italiana Linfomi - ETS
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-23
- Primary completion
- 2028-11-01
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.